This week in therapeutics




Licensing status

Publication and contact information

Ophthalmic disease

Age-related macular degeneration (AMD); retinitis

PC4 and SFRS1-interacting protein (PSIP1; LEDGF; p75; LEDGF/p75)

Cell culture and rat studies suggest the lens epithelium-derived growth factor fragment LEDGF1-326 could help treat dry AMD and retinitis pigmentosa (RP). In retinal cell culture, the fragment decreased protein aggregation-mediated stress and cell death compared with no protein fragment. In a rat model for dry AMD and RP, intravitreal injection of LEDGF1-326 decreased photoreceptor loss compared with vehicle injection. Next steps include evaluating the safety of LEDGF1-326 compositions in animal models and assessing the effectiveness of using the protein fragment to treat protein aggregation diseases of the brain.

SciBX 6(21); doi:10.1038/scibx.2013.527
Published online May 30, 2013

Patent application filed covering compositions and methods of treatment; available for licensing from the University of Colorado Denver Technology Transfer Office
Contact: David Poticha, University of Colorado Denver, Aurora, Colo.

Baid, R. et al. J. Biol. Chem.; published online May 2, 2013;
Contact: Uday B. Kompella, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colo.